342 related articles for article (PubMed ID: 16763008)
1. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
Milsom I; Lete I; Bjertnaes A; Rokstad K; Lindh I; Gruber CJ; Birkhäuser MH; Aubeny E; Knudsen T; Bastianelli C
Hum Reprod; 2006 Sep; 21(9):2304-11. PubMed ID: 16763008
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone.
Ahrendt HJ; Nisand I; Bastianelli C; Gómez MA; Gemzell-Danielsson K; Urdl W; Karskov B; Oeyen L; Bitzer J; Page G; Milsom I
Contraception; 2006 Dec; 74(6):451-7. PubMed ID: 17157101
[TBL] [Abstract][Full Text] [Related]
3. Lower hormone dosage with improved cycle control.
Vree M
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 2():25-30; discussion 37-9. PubMed ID: 12659399
[TBL] [Abstract][Full Text] [Related]
4. Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone).
Mohamed AM; El-Sherbiny WS; Mostafa WA
Int J Gynaecol Obstet; 2011 Aug; 114(2):145-8. PubMed ID: 21669426
[TBL] [Abstract][Full Text] [Related]
5. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel: a randomized trial.
Oddsson K; Leifels-Fischer B; Wiel-Masson D; de Melo NR; Benedetto C; Verhoeven CH; Dieben TO
Hum Reprod; 2005 Feb; 20(2):557-62. PubMed ID: 15539438
[TBL] [Abstract][Full Text] [Related]
6. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
[TBL] [Abstract][Full Text] [Related]
7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive in Chinese women: a 1-year randomised trial.
Fan GS; Ren M; Di W; Su P; Chang Q; Wu S; Qin Y; Korver T; Marintcheva-Petrova M; Yacik C; McCrary Sisk C; Wang G
Eur J Contracept Reprod Health Care; 2016 Aug; 21(4):303-9. PubMed ID: 27339759
[TBL] [Abstract][Full Text] [Related]
9. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO
Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061
[TBL] [Abstract][Full Text] [Related]
10. An open-label, multicentre trial to evaluate the vaginal bleeding pattern of the combined contraceptive vaginal ring NuvaRing.
Bruni V; Pontello V; Luisi S; Petraglia F
Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):65-71. PubMed ID: 18358586
[TBL] [Abstract][Full Text] [Related]
11. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol.
Kluft C; Endrikat J; Mulder SM; Gerlinger C; Heithecker R
Contraception; 2006 Apr; 73(4):336-43. PubMed ID: 16531162
[TBL] [Abstract][Full Text] [Related]
12. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
13. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
14. Comparison of uterine concentrations of ethinyl estradiol and etonogestrel after use of a contraceptive vaginal ring and an oral contraceptive.
Roumen FJ; Dieben TO
Fertil Steril; 2006 Jan; 85(1):57-62. PubMed ID: 16412731
[TBL] [Abstract][Full Text] [Related]
15. The combined contraceptive vaginal device (NuvaRing): a comprehensive review.
Sarkar NN
Eur J Contracept Reprod Health Care; 2005 Jun; 10(2):73-8. PubMed ID: 16147810
[TBL] [Abstract][Full Text] [Related]
16. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
Vree ML; Schmidt J
Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
[TBL] [Abstract][Full Text] [Related]
17. [Combined hormonal contraception in cycles artificially extended].
Bustillos-Alamilla E; Zepeda-Zaragoza J; Hernández-Ruiz MA; Briones-Landa CH
Ginecol Obstet Mex; 2010 Jan; 78(1):37-45. PubMed ID: 20931801
[TBL] [Abstract][Full Text] [Related]
18. A study of cycle control, side effects and client's satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone (24/4 regimen).
Chaiyasit N; Taneepanichskul S
J Med Assoc Thai; 2010 May; 93(5):517-22. PubMed ID: 20524436
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.
van den Heuvel MW; van Bragt AJ; Alnabawy AK; Kaptein MC
Contraception; 2005 Sep; 72(3):168-74. PubMed ID: 16102549
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with NuvaRing in daily practice in Switzerland: cycle control and acceptability among women of all reproductive ages.
Merki-Feld GS; Hund M
Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):240-7. PubMed ID: 17763262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]